Patents by Inventor Brian G. Athos

Brian G. Athos has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10391125
    Abstract: Nanosecond pulsed electric field (nsPEF) treatments of a tumor are adjusted based on a size and type of the tumor to stimulate an immune response against the tumor and other tumors in the subject. Calreticulin expression on tumor cells can be detected to confirm treatment. An immune response biomarker can be measured, and further nsPEF treatments can be performed if needed to stimulate or further stimulate the immune response. Cancers that have metastasized may be treated by directly treating a tumor that is most accessible. The treatment can be combined with CD47-blocking antibodies, doxorubicin, CTLA-4-blocking antibodies, and/or PD-1-blocking antibodies. Electrical characteristics of nsPEF treatments can be based on the size, type, and/or strength of tumors and/or a quantity of tumors in the subject.
    Type: Grant
    Filed: September 26, 2018
    Date of Patent: August 27, 2019
    Assignee: PULSE BIOSCIENCES, INC.
    Inventors: Richard Lee Nuccitelli, Pamela S. Nuccitelli, Joanne Lum, Kaying Lui, Brian G. Athos, Mark P. Kreis, Zachary R. Mallon, Jon Berridge
  • Publication number: 20190022141
    Abstract: Nanosecond pulsed electric field (nsPEF) treatments of a tumor are adjusted based on a size and type of the tumor to stimulate an immune response against the tumor and other tumors in the subject. Calreticulin expression on tumor cells can be detected to confirm treatment. An immune response biomarker can be measured, and further nsPEF treatments can be performed if needed to stimulate or further stimulate the immune response. Cancers that have metastasized may be treated by directly treating a tumor that is most accessible. The treatment can be combined with CD47-blocking antibodies, doxorubicin, CTLA-4-blocking antibodies, and/or PD-1-blocking antibodies. Electrical characteristics of nsPEF treatments can be based on the size, type, and/or strength of tumors and/or a quantity of tumors in the subject.
    Type: Application
    Filed: September 26, 2018
    Publication date: January 24, 2019
    Applicant: Pulse Biosciences, Inc.
    Inventors: Richard Lee Nuccitelli, Pamela S. Nuccitelli, Joanne Lum, Kaying Lui, Brian G. Athos, Mark P. Kreis, Zachary R. Mallon, Jon Berridge
  • Patent number: 10137152
    Abstract: A subject is inoculated from a disease by exposing a biopsy of a tumor or other abnormal growth to a nanosecond pulsed electric field (nsPEF). A sufficient treatment can be confirmed by detecting calreticulin on the tumor cell membranes, which indicates apoptosis occurring in the tumor cells. Treated tumor cells from the biopsy are then reintroduced into the subject. The calreticulin-exhibiting tumor cells activate the subject's immune system against the tumor, and any other like tumors in the body, and effectively vaccinates the subject against the disease. The treatment can be combined with CD47-blocking antibodies, doxorubicin, CTLA-4-blocking antibodies, and/or PD-1-blocking antibodies. The immune response may be measured at a later time. Specific electrical characteristics of the nsPEF treatments can be based on the type and/or strength of the tumor.
    Type: Grant
    Filed: January 17, 2018
    Date of Patent: November 27, 2018
    Assignee: Pulse Biosciences, Inc.
    Inventors: Richard Lee Nuccitelli, Pamela S. Nuccitelli, Joanne Lum, Kaying Lui, Brian G. Athos, Mark P. Kreis, Zachary R. Mallon, Jon Berridge
  • Publication number: 20180243558
    Abstract: A pulse generation system is disclosed. The pulse generation system includes a controller, an output terminal, and a plurality of pulse generator circuits. The controller is configured to cause a driving signal pulse to be transmitted to any selected one or more of the pulse generator circuits, and to cause the driving signal pulse to not be transmitted to any selected one or more other pulse generator circuits. Each of the pulse generator circuits is configured to generate an output voltage pulse at the output terminal in response to the driving signal pulse being transmitted thereto.
    Type: Application
    Filed: February 28, 2017
    Publication date: August 30, 2018
    Applicant: Pulse Biosciences, Inc.
    Inventors: Brian G. Athos, Shu Xiao, David J. Danitz, Mark P. Kreis, Darrin R. Uecker
  • Publication number: 20180153937
    Abstract: A subject is inoculated from a disease by exposing a biopsy of a tumor or other abnormal growth to a nanosecond pulsed electric field (nsPEF). A sufficient treatment can be confirmed by detecting calreticulin on the tumor cell membranes, which indicates apoptosis occurring in the tumor cells. Treated tumor cells from the biopsy are then reintroduced into the subject. The calreticulin-exhibiting tumor cells activate the subject's immune system against the tumor, and any other like tumors in the body, and effectively vaccinates the subject against the disease. The treatment can be combined with CD47-blocking antibodies, doxorubicin, CTLA-4-blocking antibodies, and/or PD-1-blocking antibodies. The immune response may be measured at a later time. Specific electrical characteristics of the nsPEF treatments can be based on the type and/or strength of the tumor.
    Type: Application
    Filed: January 17, 2018
    Publication date: June 7, 2018
    Applicant: Pulse Biosciences, Inc.
    Inventors: Richard Lee Nuccitelli, Pamela S. Nuccitelli, Joanne Lum, Kaying Lui, Brian G. Athos, Mark P. Kreis, Zachary R. Mallon, Jon Berridge
  • Publication number: 20170333112
    Abstract: An optimization of electrical characteristics for treatments of tumor or other abnormal cells in culture with sub-microsecond, high-electric field electrical pulses is disclosed. The voltages, pulse widths, and number of pulses are chosen such that the treatment energy is 10-20 J/mL. That is, U=n*?t*V*I/volume is 10-20 J/mL, in which n is the number of pulses, ?t is the duration of each pulse, V is the voltage, I is current, and volume is the area of parallel electrodes times the distance between them. V divided by the distance between the electrodes can be in an effective range of 6 kV/cm to 30 kV/cm, 60 kV/cm, 100 kV/cm, or higher intensities. Rows of needle electrodes, blade electrodes, or other configurations of electrodes can approximate parallel electrodes.
    Type: Application
    Filed: May 19, 2017
    Publication date: November 23, 2017
    Applicant: Pulse Biosciences, Inc.
    Inventors: Richard L. Nuccitelli, Zachary R. Mallon, Amanda H. McDaniel, David J. Danitz, Brian G. Athos, Mark P. Kreis, Darrin R. Uecker, Pamela S. Nuccitelli
  • Publication number: 20170319851
    Abstract: A method of testing a therapeutic pulse generator circuit is disclosed. The method includes charging the pulse generator circuit to a first charge voltage, with the pulse generator circuit, delivering a first voltage pulse to a load through an electrode, and determining an impedance of the load with the first voltage pulse. The method also includes comparing the impedance with an expected impedance, as a result of the comparison, determining to deliver a second voltage pulse to the load based, and delivering the second voltage pulse to the load, where at least one of the first and second voltage pulses is therapeutic to the load.
    Type: Application
    Filed: November 9, 2016
    Publication date: November 9, 2017
    Applicant: Pulse Biosciences, Inc.
    Inventors: Brian G. Athos, David J. Danitz, Mark P. Kreis, Darrin R. Uecker
  • Publication number: 20170246455
    Abstract: A pulse generator discharge circuit is disclosed. The circuit includes one or more discharge stages, each discharge stage including a plurality of control input terminals. The circuit also includes first and second discharge terminals, and a plurality of serially connected switches electrically connected between the first and second discharge terminals, where a conductive state of each of the switches is controlled by a control signal. The circuit also includes a plurality of inductive elements configured to generate the control signals for the serially connected switches, where each inductive element is configured to generate a control signal for one of the serially connected switches in response to one or more input signals at one or more of the control input terminals, and where each of the serially connected switches is configured to receive a control signal from a respective one of the inductive elements.
    Type: Application
    Filed: November 9, 2016
    Publication date: August 31, 2017
    Applicant: Pulse Biosciences, Inc.
    Inventors: Brian G. Athos, Darrin R. Uecker, Shu Xiao
  • Publication number: 20170245928
    Abstract: A sub-microsecond pulsed electric field generator is disclosed. The field generator includes a controller, which generates a power supply control signal and generates a pulse generator control signal, and a power supply, which receives the power supply control signal and generates one or more power voltages based on the received power supply control signal. The field generator also includes a pulse generator which receives the power voltages and the pulse generator control signal, and generates one or more pulses based on the power voltages and based on the pulse generator control signal. The controller receives feedback signals representing a value of a characteristic of or a result of the pulses and generates at least one of the power supply control signal and the pulse generator control signal based on the received feedback signals.
    Type: Application
    Filed: May 6, 2016
    Publication date: August 31, 2017
    Applicant: PULSE BIOSCIENCES, INC.
    Inventors: Shu Xiao, Brian G. Athos, Mark P. Kreis, David J. Danitz, Darrin R. Uecker
  • Publication number: 20170216353
    Abstract: A subject is inoculated from a disease by exposing a biopsy of a tumor or other abnormal growth to a nanosecond pulsed electric field (nsPEF). A sufficient treatment can be confirmed by detecting calreticulin on the tumor cell membranes, which indicates apoptosis occurring in the tumor cells. Treated tumor cells from the biopsy are then reintroduced into the subject. The calreticulin-exhibiting tumor cells activate the subject's immune system against the tumor, and any other like tumors in the body, and effectively vaccinates the subject against the disease. The treatment can be combined with CD47-blocking antibodies, doxorubicin, CTLA-4-blocking antibodies, and/or PD-1-blocking antibodies. The immune response may be measured at a later time. Specific electrical characteristics of the nsPEF treatments can be based on the type and/or strength of the tumor.
    Type: Application
    Filed: April 11, 2017
    Publication date: August 3, 2017
    Applicant: Pulse Biosciences, Inc.
    Inventors: Richard Lee Nuccitelli, Pamela S. Nuccitelli, Joanne Lum, Kaying Lui, Brian G. Athos, Mark P. Kreis, Zachary R. Mallon, Jon Berridge
  • Publication number: 20170117603
    Abstract: A high-voltage coaxial cable with a hollow inner conductor is described. The hollow region can be filled with a non-conducting filler. The inner conductor is surrounded by a dielectric, which is surrounded by an outer conductor and jacket. Methods and systems for designing these very high voltage coaxial cables with matching system impedance and minimal cable cross sections are provided. Embodiments include coaxial cables, systems, and methods for designing coaxial cables with high standoff voltage capacity, greater flexibility than standard coaxial cable, and a given impedance. Embodiments provide setting the requirements for an insulator of a coaxial cable driving the dimensions of the other components of the coaxial cable.
    Type: Application
    Filed: October 21, 2016
    Publication date: April 27, 2017
    Applicant: Pulse Biosciences, Inc.
    Inventors: Mark P. Kreis, Brian G. Athos